Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05397782 · ClinicalTrials.gov registry record · NA

Effects of Flourish on Recurrent Urinary Tract Infection

A NA study, sponsored by Vaginal Biome Science.

Completed
Registry status
NA
Development phase
14
Enrollment target

NCT05397782: Completed NA study, sponsored by Vaginal Biome Science.

NCT05397782 is a NA study that has completed, run by Vaginal Biome Science. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05397782, a NA study, has completed, sponsored by Vaginal Biome Science.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target

Study Summary

An over-the-counter vaginal care system is being tested to see if it may be effective in preventing recurrence of symptomatic urinary tract infection (UTI) in women who have had multiple UTIs within the past year.

Primary Outcome

The vaginal microbiome will be assessed using next-generation sequencing (NGS) technology to assign the biome to one of 5 "community state types" (CST). The outcome will examine whether the vaginal microbiome changes from an unhealthy one (IV or III) to a healthy one (I, II, or V).

Interventions

  • DEVICE BioNourish, a component of Flourish HEC

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2022-09-26
Est. Completion 2024-02-21
Phase NA
Vaginal Biome Science

9 total trials

What the finished NCT05397782 record still lists

NCT05397782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which BioNourish, a component of Flourish HEC is the first listed.

NCT05397782 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05397782 about?

NCT05397782 is a clinical study titled "Effects of Flourish on Recurrent Urinary Tract Infection". An over-the-counter vaginal care system is being tested to see if it may be effective in preventing recurrence of symptomatic urinary tract infection (UTI) in women who have had multiple UTIs within the past year.

What is the current status of trial NCT05397782?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2022-09-26. Estimated completion is 2024-02-21.

What interventions are being tested in trial NCT05397782?

The interventions under investigation include: BioNourish, a component of Flourish HEC (DEVICE).

Who is sponsoring clinical trial NCT05397782?

This trial is sponsored by Vaginal Biome Science, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05397782's enrollment target sits among peer trials

14 1909th of 2000 higher than 90 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT05397782, the US trial registry maintained by the National Library of Medicine. NCT05397782 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.